Summary A small pre-treatment 'priming' dose of cyclophosphamide will reduce gut damage due to high dose i.v. melphalan in mice and sheep but efforts to demonstrate this effect in man have been hampered by difficulty in the measurement of gut damage. We have evaluated the "CR EDTA absorption test, a new method for measuring intestinal permeability, as a means of assessing damage due to high dose melphalan. The test was reliable, with a narrow normal range, easy to use and well tolerated. It detected an increase in intestinal permeability after high dose melphalan with a maximum occurring between 9 and 15 days after treatment and subsequently returning to normal. It was shown in 19 patients that a pre-treatment dose of cyclophosphamide was capable of significantly reducing the abnormalities in intestinal permeability which resulted from high dose melphalan.
The proliferating epithelium of the intestine is damaged by some cancer chemotherapy and by radiotherapy (Shaw et al., 1979) . The doses of these treatments which may be given are frequently limited by gut damage. In studies with high dose intravenous melphalan it has been shown that when autologous bone marrow transplantation is used, the toxicity which prevents further increase in the dose of melphalan is intestinal damage (McElwain et al., 1979; Cornbleet et al., 1983) . In experimental systems this gut damage can be reduced by pre-treatment of animals with a 'priming' dose of cyclophosphamide given 2 days before the melphalan in mice and 7 days in sheep (Millar et al., 1978) .
It has been difficult to evaluate the priming effect in man because of the absence of an acceptable method for measuring intestinal damage. Simple conventional methods for measuring gut damage appear to be insensitive or unreliable when applied to the measurement of cytotoxic effects. More elaborate or invasive methods cannot be readily used in this patient population who are usually unwell and predisposed to infection or bleeding. For example, although studies at this hospital using a simple xylose absorption test have shown functional abnormalities after methotrexate given for maintenance treatment in acute childhood leukaemia (Craft et al., 1977) , we have found this test to be poorly tolerated and unreliable in patients receiving more intensive treatments.
The 5"chromium edetic acid (EDTA) absorption test was introduced as a sensitive, reliable and valid measurement for intestinal permeability in patients with coeliac disease Editorial, 1985) . EDTA is an inert molecule which is normally absorbed from the intestine in very small quantities. Damage to the epithelium renders it more permeable allowing increased absorption into the blood stream, probably between cells rather than by an intracellular uptake. Subsequently the molecule is filtered in the kidneys and excreted in the urine. Increased excretion of 5"chromium EDTA in urine after an oral dose indicates increased intestinal permeability (Selby et al., 1984 Thirty-three cancer patients (18 M; 15 F) of mean age 32 yrs (range 10-59 yrs) who had received no cytotoxic treatment for at least I month formed the control population. Three of these gave a history of heavy alcohol intake immediately before testing and they were subsequently excluded from the control group (Draper et al., 1983) . In three patients, repeated tests were possible before any treatment was given and the results compared.
We applied the test sequentially at 5-8 day intervals in two groups of patients:-.. In 30 untreated patients, the mean 24h 5"Cr EDTA excretion in urine was 1.7% of administered dose with standard deviation 0.58% (Figure 1) . Three other untreated patients gave a history of heavy alcohol intake and their excretion values were 4.1, 5.6 and 5.9%. These three are excluded from our normal range which extends up to 2.9%.
Nineteen patients (
In the three untreated patients in whom the test was done twice the results agreed closely.
Duration of excretion of 51Cr EDTA In eight patients, urine was collected for 3 days and the daily excretion of 51Cr EDTA estimated (Figure 2 ). The excretion fell rapidly and had reached low levels during the third day. However, a significant proportion of the dose was excreted between 24 and 48 h for some patients and so an initial 24 h period of collection may underestimate the total absorption of EDTA in these patients.
Serial collections after cytotoxic treatment
The test was performed sequentially after treatment at intervals of -5 days.
(i) High dose melphalan (180-220 mgm-2) with autologous marrow grafting The test became abnormal after one week and returned to normal after two weeks (Figure 3) . The data suggest that the time of maximum increase in gut permeability was at about day 9. All of these patients experienced diarrhoea after their melphalan treatment, beginning after one and continuing for about one week as described by Cornbleet et al. (1983) . Melphalan (mg m-2) CY = Cyclophosphamide prime (P < 0.01) Figure 1 Maximal 24 h urinary excretion of 5tCr EDTA in patients after i.v. melphalan 180mgm-2 or 200-220mgm-2 compared to untreated controls. The patients treated at the higher dose levels were randomly allocated to cyclophosphamide priming and the primed group have significantly lower 'Cr EDTA excretion (P<0.01 using a t test and Fisher's exact test).
Median 24 h excretion in controls was 1.7% compared to median maximal excretion of 3.1% in patients receiving 200-220mgm-2 melphalan with cyclophosphamide priming and 7.4% in patients given the same melphalan dose but no priming. There were no significant differences in timing of studies between the groups.
Gut damage increased with increased melphalan dose and the peak abnormality was significantly greater after melphalan 200 mg m 2 than after melphalan 180mg m -2 (P = 0.05 Wilcoxon Rank Sum Test). Among patients who received 200-220mgm 2 of melphalan, the first 8 received 200 mgm 2 and the next 7 received 220mgm-2. They were randomly allocated within each dose level to receive a cyclophosphamide prime or not. The maximum measured excretion of EDTA was significantly lower in the patients who received a cyclophosphamide prime (Figure 1, P<0 (ii) High dose cyclophosphamide Two patients received cyclophosphamide 7 g m-2 i.v. without bone marrow grafting. No abnormalities were observed in their intestinal permeability.
Renal function Since renal clearance of 51Cr EDTA might be expected to influence the speed of excretion of the absorbed oral dose, creatinine clearance was measured on each 24 h urine. Change in urine excretion of 51Cr EDTA in the first 24 h were not explained by changes in creatinine clearance.
Discussion
The 51Cr EDTA absorption test was easy to perform and generally well tolerated by our patients even after intensive cytotoxic therapies. 5"Cr edetic acid is cheap, stable and widely used in Nuclear Medicine. The test was reliable and had a narrow normal range although interfering factors such as heavy alcohol intake must be identified . Collection of urine for longer than 24 h might increase its sensitivity but is time consuming for patients and was not necessary for the purposes of this study.
Abnormalities due to melphalan were detected at doses above 180 mgm-2 and seemed to be dose-dependent. The timing of these abnormalities was similar to the timing of histological gut abnormalities after cytotoxic treatment in serial biopsy studies in man (Lubitz & Ekert, 1979; Cornbleet et al., 1983) . No intestinal abnormalities were shown after cyclophosphamide treatment which is in keeping with previous evidence for this drug (Shaw et al., 1979) .
Although the numbers of patients are not great, we have demonstrated a significant reduction in gut damage after melphalan by cyclophosphamide priming. The effect is quite small and probably not greater than a dose change of 20-40mg. Its mechanism is not known (Millar & McElwain, 1985) but further investigation of mechanism and of the optimal timing of the priming dose may allow further reduction in gut damage.
